Senior Manager / Associate Director, Health Economics & HTA, China

By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that the information I provide in my application will be processed in line with Takeda’s Privacy Notice and Terms of Use . I further attest that all information I submit in my employment application is true to the best of my knowledge. Job Description OBJECTIVES/PURPOSE Leads the development and execution of integrated health economics (HE) and health technology assessment (HTA) strategies for China, translating payer, policy, clinical, patient, and economic evidence needs into scientifically robust, locally relevant, feasible, and compliant plans. Serves as the strategic HE/HTA lead and trusted advisor for assigned pipeline and in-line assets [current focus: Gastroenterology (GI), Immunology, Rare Disease (RD), and Plasma-Derived Therapy (PDT), with scope determined by portfolio priorities], advocating for China-specific evidence needs and access priorities and influencing local, regional, and global integrated evidence generation planning (IEP), value strategy, investment decisions, and research priorities across the product lifecycle. Provides scientific, technical, operational, and financial leadership for economic evidence generation, health economic modeling, HTA landscape assessment and scenario planning, value frameworks, HTA evidence packages, and value dossiers to inform pricing and reimbursement decisions, National Reimbursement Drug List (NRDL) submissions and negotiations, commercial health insurance coverage, and other priority access pathways. Provides authoritative oversight of the China HE/HTA portfolio, including prioritization, budgets, external partnerships, resources, timelines, risk management, scientific quality, value communication, and compliant delivery. Drives responsible digital innovation by leveraging fit-for-purpose data, advanced analytics, automation, and AI-enabled tools to strengthen HE/HTA strategy, economic modeling, evidence synthesis, and data-driven decision-making, with appropriate human oversight, validation, verification, transparency, confidentiality, and accountability. ACCOUNTABILITIES Develops and communicates integrated China HE/HTA strategies and evidence plans for assigned assets, ensuring that prioritized local needs are incorporated into global IEPs and aligned with product development stage, China access and medical priorities, and brand and launch plans. Leads assessment of the evolving HTA, reimbursement, and payer landscape in China and relevant international markets, identifying evidence needs, risks, opportunities, and implications for asset and portfolio strategy. Leads HTA scenario planning to evaluate alternative evidence, pricing, reimbursement, and policy environments and inform evidence investment, access strategy, and decision-making. Leads cross-functional discussions to align HE/HTA priorities, methods, assumptions, outputs, and intended uses with Market Access, Medical Affairs, Commercial, Global Medical Evidence Generation, and other relevant partners. Leads the end-to-end design and delivery of HE/HTA projects, including cost-effectiveness and cost-utility analyses, budget impact analyses, burden-of-illness and utility studies, evidence synthesis, indirect treatment comparisons for HTA or payer use, HTA evidence packages, value dossiers, and approved value communication tools. Leads or oversees the development, localization, validation, and interpretation of health economic models, ensuring that structure, comparators, time horizons, assumptions, inputs, uncertainty, limitations, and conclusions are transparent, scientifically robust, and relevant to China. Defines data requirements for economic evaluation and HTA and integrates fit-for-purpose China epidemiology, clinical outcomes, healthcare resource utilization, cost, utility, patient-reported outcome, and other relevant inputs, partnering with RWE, Epidemiology, COA/PED, and other evidence teams where appropriate. Develops and applies value frameworks and value narratives that integrate clinical, patient, economic, and healthcare-system outcomes to support HTA, reimbursement, and stakeholder decision-making. Ensures that patient perspectives, clinical outcome assessments, patient experience data, patient-reported outcomes, and patient-centered value are appropriately incorporated into HTA strategy, economic evaluation, evidence packages, and value communication. Provides critical scientific and technical review of health economic models, specifications, analysis plans, reports, HTA evidence packages, value dossiers, publications, and other HE/HTA deliverables, ensuring that analyses are robust, transparent, reproducible, and fit for purpose. Provides strategic recommendations on HE/HTA investment, project sequencing, model and data strategy, resource allocation, and portfolio prioritization based on decision value, access impact, feasibility, timing, quality, and risk. Leverages digital platforms, advanced analytics, automation, data visualization, and AI-enabled tools for economic modeling, evidence synthesis, literature review, quality checks, scenario analysis, and communication; critically evaluates AI-assisted outputs and ensures human accountability, verification, transparency, data confidentiality, and compliant use. Represents China in relevant global HE/HTA, value, access, product, and launch workshops, contributing China-specific payer, policy, method, and data insights and leading fit-for-purpose localization of global models, evidence deliverables, and systematic or targeted literature reviews. Collaborates with regional and global teams on joint clinical assessments, joint scientific consultation, and other global HTA initiatives where relevant, and supports the interpretation and application of their outputs in the China context. Manages external experts, academic collaborators, research organizations, consultants, and other vendors to ensure delivery of scientifically robust, high-quality, compliant, and fit-for-purpose outputs within agreed scope, budget, and timelines. Builds trusted, compliant relationships with HE/HTA and pharmacoeconomics experts, academic institutions, payers, clinicians, and professional societies; leads advisory boards, expert consultations, scientific exchange, and selected innovation pilots where appropriate. Provides HE/HTA expertise, coaching, and training to colleagues and contributes to continuous improvement of methods, governance, templates, quality controls, digital capabilities, and ways of working. Ensures all economic evidence generation, modeling, data use, external engagement, publication, value communication, and dissemination activities comply with applicable laws and regulations, company policies and procedures, ethical standards, scientific good practice, and data privacy and security requirements, and supports local audit and inspection readiness. EDUCATION, BEHAVIOURAL COMPETENCIES AND SKILLS Required: Master’s degree or above in health economics, pharmacoeconomics, health outcomes research, health policy, public health, epidemiology, data science, biostatistics, pharmacy, or a related discipline; a doctoral degree is preferred. At least 8 years of relevant HE/HEOR, HTA, value and access, or economic evidence generation experience in the pharmaceutical or biotechnology industry, consultancy, academia, research organizatio